Atorvastatin calcium: EFFICACY(5)
In a recent multicentre, randomized, parallel-group study, he comparative dose efficacy of atorvastatin at all doses was directly compared with all doses of simvastatin, pravastatin, ovastatin and fluvastatin in patients with mild to moderate hypercholesterolemia. This is the first time that the effec-:iveness of available HMG-CoA reductase inhibitors has been valuated in a single trial.
The results showed that, at its start-ng dose of 10 mg/day, atorvastatin produced significantly greater reductions in total cholesterol and LDL-C levels compared with the starting doses of all other HMG-CoA reduc-:ase inhibitors (simvastatin 10 mg/day, or pravastatin, ovastatin or fluvastatin 20 mg/day) (Figure 2). The LDL-C owering efficacy of atorvastatin 10 mg/day (38.2%) was comparable with or greater than that observed with simvastatin 10 mg/day (41%), pravastatin 40 mg/day (33.7%), lovastatin 10 mg/day (31.4%) and fluvastatin 40 mg/day (23%). At higher doses, the reduction in LDL-C level with atorvastatin was greater than that observed with the higher doses of the ther HMG-CoA reductase inhibitors. Additionally, atorvas-atin provided greater reductions in elevated levels of total holesterol and triglycerides. buy ampicillin
Figure 2) Efficacy of hydroxy-methyl-glutaryl coenzyme A reductase nhibitors in patients with mild to moderate hypercholesterolemia in a single comparative-dose study. LDL-C Low density lipoprotein cho-esterol. Reprinted from The American Journal of Cardiology, Volume 31, Jones et al, “Comparative dose efficacy study of atorvastatin ver-us simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)”, pages582-7. Copy-ight with permission from Excerpta Medica Inc